Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
October, 2026
October 2026
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  
Alan Nurden: Disrupting Pathogenic Alleles in VWD Through Gene Editing
Alan Nurden/issue.com; Isabel Bär/LinkedIn
Apr 5, 2026, 08:19

Alan Nurden: Disrupting Pathogenic Alleles in VWD Through Gene Editing

Alan Nurden, Emeritus Research Director at CNRS, Co-Founder of the French National Reference Centre for Inherited Platelet Disorders (CRPP), shared a post on LinkedIn about a recent article by Isabel Bär et al. published in Blood advances, adding:

“Like for most inherited platelet disorders, gene therapy has been slow in arriving for patients with von Willebrand disease (VWD).

While the heterogeneity of VWD adds to the complexity of treatment, the targeting of endothelial cells that extend throughout the vasculature is also a challenge.

In this study, Isabel Bär and her colleagues from the Netherlands, show proof of principle for a novel, approach for universal inactivation of dominant VWD variants by selectively disrupting the open reading frame of the mutated allelle.

CAS9 nuclease is used to introduce indels that transform the pathogenic allele into a null allele, the non-affected normal allele synthesizes enough VWF for it to assume normal hemostatic functions.

The question is whether this approach can be applied to other bleeding disorders including the megakaryocyte-derived autosomal dominant Glanzmann thrombasthenia-related disease or mono-allelic Bernard-Soulier syndrome where loss of platelet function is accompanied by macrothrombocytopenia.

As for endothelial cells, the key will be to adequately and specifically delete the disease-causing allele and in sufficient quantities to correct megakaryocytic maturation and increase platelet numbers.

Advances are being made to genetically correct the origins of blood disorders and this impressive manuscript is highly recommended.”

Title: Allele-selective disruption of pathogenic VWF variants in type 2 von Willebrand disease using CRISPR/Cas9

Authors: Isabel Bär, Stijn A. Groten, Alastair Barraclough, Petra E. Bürgisser, Calvin van Kwawegen, Peter J. Lenting, Iris van Moort, Jeroen C. J. Eikenboom, Frank W. G. Leebeek, Jan Voorberg, Maartje van den Biggelaar, Ruben Bierings

Read the Full Article on Blood advances

Alan Nurden: Disrupting Pathogenic Alleles in VWD Through Gene Editing

Other posts featuring Alan Nurden on Hemostasis Today.

Alastair Barraclough Bernard–Soulier Syndrome bleeding disorders Calvin van Kwawegen Frank W. G. Leebeek Glanzmann thrombasthenia Health Hematology Hemostasis Hemostasis News Hemostasis Today Iris van Moort Isabel Bär Jan Voorberg Jeroen C.J. Eikenboom Maartje van den Biggelaar Peter J   Lenting Petra E. Bürgisser Ruben Bierings Stijn A. Groten Von Willebrand Disease VWD
NewsFeed